Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Actinic Keratosis
Interventions
DRUG

LEO 43204

DRUG

Placebo

Trial Locations (21)

15213

University of Pittsburgh Medical Center, Pittsburgh

20850

DermAssociates, PC, Rockville

32174

Leavitt Medical Associates of Florida, Ormond Beach

33134

Dermatology Associates and Research, Coral Gables

46168

Indiana Clinical Trials Center, Plainfield

47713

Deaconess Clinic, Inc., Evansville

47714

Hudson Dermatology, LLC, Evansville

48706

Great Lakes Research Group, Inc., Bay City

78660

Pflugerville Dermatology Clinical Research Center, Inc., Pflugerville

85018

Omni Dermatology, Phoenix

90717

Torrance Clinical Research Institute Inc., Lomita

92121

Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc., San Diego

07044

The Dermatology Group, P.C., Verona

T2G 1B1

Kirk Barber Research, Calgary

V3R 6A7

Enverus Medical, Surrey

V5Z 4E8

Skin Care Centre, Vancouver

R3C 0N2

Winnipeg Clinic Dermatology Research, Winnipeg

L4M 6L2

UltraNova Skincare, Barrie

L8N 1V6

Dermatrials Research Incorporated, Hamilton

N6A 3H7

The Guenther Dermatology Research Centre, London

K9J 1Z2

SKiN Centre for Dermatology, Peterborough

Sponsors

Lead Sponsor

All Listed Sponsors
lead

LEO Pharma

INDUSTRY